T. Rowe Price Associates’s Alpine Immune Sciences Inc ALPN Stock Holding History

T. Rowe Price Associates’s Portfolio ALPN Stock Details ALPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-3,080,220	Closed	-$122M	–	3071
2024 Q1	$122M	Buy	3,080,220 +1,392,942	+83%	+$41.1M	0.02%	506
2023 Q4	$32.2M	Buy	1,687,278 +290,834	+21%	+$4.04M	﹤0.01%	830
2023 Q3	$16M	Buy	1,396,444 +1,374,704	+6,323%	+$16.9M	﹤0.01%	974
2023 Q2	$224K	Buy	21,740 +2,115	+11%	+$19.1K	﹤0.01%	2482
2023 Q1	$152K	Buy	19,625 +224	+1%	+$1.78K	﹤0.01%	2592
2022 Q4	$143K	Buy	19,401 +6,786	+54%	+$43.4K	﹤0.01%	2633
2022 Q3	$91K	Buy	+12,615	New	+$104K	﹤0.01%	2747

T. Rowe Price Associates's ALPN Position: Q2 2024 in Review

T. Rowe Price Associates sold out of Alpine Immune Sciences Inc (ALPN) in Q2 2024, closing a stake of 3,080,220 shares — an estimated $122M sold.

T. Rowe Price Associates first reported a position in ALPN in Q3 2022 and held it in 7 quarters. The position peaked at $122M in Q1 2024. 0 funds tracked by Wall St. Rank hold ALPN as of Q2 2024.

T. Rowe Price Associates reported no remaining Alpine Immune Sciences Inc position as of Q2 2024 after selling out during the quarter.
T. Rowe Price Associates sold 3,080,220 Alpine Immune Sciences Inc shares in Q2 2024, an estimated $122M.
T. Rowe Price Associates first reported a position in Alpine Immune Sciences Inc in Q3 2022 and held it in 7 quarters.
T. Rowe Price Associates's Alpine Immune Sciences Inc position peaked at $122M in Q1 2024.
0 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q2 2024.

Based on T. Rowe Price Associates's 13F filing for Q2 2024, filed 14 Aug 2024.